These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39393872)

  • 1. [TVE in the management of rare diseases in hematology: raising the "Dephi" bar].
    Dorbon C; Houdoin V; Celerier M; Rodrigues B
    Rev Infirm; 2024 Oct; 73(304):40-42. PubMed ID: 39393872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [4th Congress of the Société Française d'Hématologie Robert Waitz Congress, Strasburg 25-29 June 1979].
    Nouv Rev Fr Hematol (1978); 1979; Suppl():I-CXLVII. PubMed ID: 44550
    [No Abstract]   [Full Text] [Related]  

  • 3. [The French rare diseases plan and learned society: situation in pediatric hematology and immunology].
    Donadieu J
    Arch Pediatr; 2010 Jun; 17(6):729-30. PubMed ID: 20654863
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. DBA group of Société d'Hématologie et d'Immunologie Pédiatrique (SHIP), Gesellshaft für Pädiatrische Onkologie und Hämatologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPHI).
    Willig TN; Niemeyer CM; Leblanc T; Tiemann C; Robert A; Budde J; Lambiliotte A; Kohne E; Souillet G; Eber S; Stephan JL; Girot R; Bordigoni P; Cornu G; Blanche S; Guillard JM; Mohandas N; Tchernia G
    Pediatr Res; 1999 Nov; 46(5):553-61. PubMed ID: 10541318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Centre de Transfusion sanguine et d'Hematologie de Toulouse].
    LEFEBVRE C; RUFFIE J; DUCOS J; BIERME R; BOURBON P; BREUILLAUD J
    Toulouse Med; 1961 Oct; 62():631-42. PubMed ID: 14463645
    [No Abstract]   [Full Text] [Related]  

  • 6. [Myelodysplastic syndromes in children, Groupe d'étude des myélodysplasies de l'enfant de la Société d'hématologie et d'immunologie pédiatrique (SHIP)].
    Bader-Meunier B; Tchernia G; Buisine J; Miélot F; Sommelet D; Dommergues JP
    Arch Pediatr; 1997 Jun; 4(6):561-7. PubMed ID: 9239274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A TPE programme for patients with neurodegenerative diseases and their carers].
    Lissot C; Garnier V; Cerles M; Uhlenbusch S; Monfort E; Couturier P
    Rev Infirm; 2021 Mar; 70(269):24-25. PubMed ID: 33742587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ["Current Issues in Hematology 2002" continuing education course--review and prospects for the future].
    Demeter J
    Magy Onkol; 2003; 47(2):221-2. PubMed ID: 14655687
    [No Abstract]   [Full Text] [Related]  

  • 9. [Evans' syndrome: a retrospective study from the ship (French Society of Pediatric Hematology and Immunology) (36 cases)].
    Blouin P; Auvrignon A; Pagnier A; Thuret I; Antoni G; Bader-Meunier B; Le Deist F; Chastagner P; Aladjidi N; Pellier I; Bertrand Y; Behar C; Landmann-Parker J; Leverger G; Perel Y
    Arch Pediatr; 2005 Nov; 12(11):1600-7. PubMed ID: 16185853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Institut d'Hematologie of Montpellier].
    CAZAL P
    Montp Med; 1959 Dec; 56():249-51. PubMed ID: 13808661
    [No Abstract]   [Full Text] [Related]  

  • 11. [Societé Française d'Hématologie, address of incoming president].
    PREVOT AR
    Sang; 1951; 22(7):563-5. PubMed ID: 14876299
    [No Abstract]   [Full Text] [Related]  

  • 12. Guidelines in hematology.
    Baccarani M; Lo Coco F; Bacigalupo A
    Haematologica; 2002 Dec; 87(12):1239-40. PubMed ID: 12495895
    [No Abstract]   [Full Text] [Related]  

  • 13. Can the 72-hour rule based on "Blast/Abn Lymph" flag on Sysmex XN-10 optimize the workflow in hematology laboratory?
    Paridaens H; Sabor L; Simar J; Ronez E; Cornet E; Defour JP
    Ann Biol Clin (Paris); 2019 Aug; 77(4):422-428. PubMed ID: 31418703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemophilia patient education: teaching and assessment of 10 programs].
    Ané AM; Wintz L; Sannié T; Gagnayre R
    Sante Publique; 2011; 23(2):123-34. PubMed ID: 21896226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Introduction to recommendations for the cytogenetic management of hematopoietic diseases].
    Dastugue N;
    Pathol Biol (Paris); 2004 Jun; 52(5):235-7. PubMed ID: 15217701
    [No Abstract]   [Full Text] [Related]  

  • 16. Highlights in gene therapy and alternative therapies in nonmalignant hematology from the 2016 American Society of Hematology meeting.
    Clin Adv Hematol Oncol; 2017 Feb; 15(2):113-116. PubMed ID: 28398280
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic assessment, 1956-1961. Hematology].
    MARCHAL G; BILSKI-PASQUIER G; CHARON P
    Gaz Med Fr; 1956-1961; (Special)():145-56. PubMed ID: 14469603
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapeutic progress in hematology].
    PAVLOVSKY A
    Dia Med; 1956 Aug; 28(Anniversary No):34; passim. PubMed ID: 13375356
    [No Abstract]   [Full Text] [Related]  

  • 19. [Changes in the diagnostic and treatment strategies of patients with hematological diseases during the COVID-19 pandemic with reference to recommendations from American Society of Hematology and European Hematology Association].
    Mori SI
    Rinsho Ketsueki; 2021; 62(2):101-105. PubMed ID: 33678768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare and difficult to treat haematological diseases.
    Lancet Haematol; 2015 Jan; 2(1):e1. PubMed ID: 26687422
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.